+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Companion Diagnostics - Global Market Trajectory & Analytics

  • ID: 1946799
  • Report
  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc

FEATURED COMPANIES

  • Abbott Molecular
  • bioMérieux SA
  • Cepheid
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
Global Companion Diagnostics Market to Reach $9.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Companion Diagnostics estimated at US$3.4 Billion in the year 2020, is projected to reach a revised size of US$9.2 Billion by 2027, growing at a CAGR of 15.1% over the period 2020-2027. Assay kits & Reagents, one of the segments analyzed in the report, is projected to record 14.3% CAGR and reach US$6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software & Services segment is readjusted to a revised 16.8% CAGR for the next 7-year period.



The U.S. Market is Estimated at $1 Billion, While China is Forecast to Grow at 14.6% CAGR

The Companion Diagnostics market in the U.S. is estimated at US$1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 14.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.5% and 13% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.1% CAGR.

Select Competitors (Total 80 Featured):
  • Abbott Molecular
  • Agilent Technologies, Inc.
  • bioMérieux SA
  • Cepheid
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
  • Laboratory Corporation of America® Holdings
  • Leica Biosystems Nussloch GmbH
  • Merck & Co. Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Inc.
  • Thermo Fischer Scientific Inc.
Frequently Asked Questions about the Global Market for Companion Diagnostics

What is the estimated value of the Global Market for Companion Diagnostics?

The Global Market for Companion Diagnostics was estimated to be valued at $3.4 Billion in 2020.

What is the growth rate of the Global Market for Companion Diagnostics?

The growth rate of the Global Market for Companion Diagnostics is 15.3%, with an estimated value of $9.2 Billion by 2027.

What is the forecasted size of the Global Market for Companion Diagnostics?

The Global Market for Companion Diagnostics is estimated to be worth $9.2 Billion by 2027.

Who are the key companies in the Global Market for Companion Diagnostics?

Key companies in the Global Market for Companion Diagnostics include Abbott Molecular, Agilent Technologies, Inc., bioMérieux SA, Cepheid, Danaher Corporation, F. Hoffmann, La Roche Ltd., Foundation Medicine Inc. and Leica Biosystems Nussloch GmbH.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Molecular
  • bioMérieux SA
  • Cepheid
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Companion Diagnostics: An Introductory Prelude
  • Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development
  • Broader Scope and Applications Rev Up Growth Opportunities
  • Healthy Growth Projected over the Next Few Years
  • Developed Regions: Key Revenue Contributors
  • Market Witnesses Fast Paced Growth in Developing Regions
  • Northbound Trajectory in R&D Spending Creates Conducive Environment
  • Prevailing Economic Scenario Favors Funding Pattern
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
  • Growing Significance of Personalized Medicine Remains a Major Market Driver
  • Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum
  • Herceptin Lays the Road for Companion Diagnostics
  • Oncology - Dominant Therapy Area for CDx
  • Rising Incidence of Cancer Propels the Need for CDx Tests
  • Technology Advancements to Widen CDx Use Case
  • PCR: Dominant Technology Type for CDx Testing
  • Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing
  • Significant Role of Biomarkers in Companion Diagnostics
  • Critical Healthcare Needs of Aging Population Underpin CDx Sales
  • Regulatory Scenario Favors CDx Market
  • Resolving Prevailing Challenges: Critical for Future Growth of CDx Market
4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS
  • UNITED STATES
  • CANADA
  • JAPAN
  • CHINA
  • EUROPE
  • FRANCE
  • GERMANY
  • ITALY
  • UNITED KINGDOM
  • REST OF EUROPE
  • ASIA-PACIFIC
  • REST OF WORLD
IV. COMPETITION
  • Total Companies Profiled: 80
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Abbott Molecular
  • Agilent Technologies, Inc.
  • bioMérieux SA
  • Cepheid
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
  • Laboratory Corporation of America® Holdings
  • Leica Biosystems Nussloch GmbH
  • Merck & Co. Inc.
  • Myriad Genetics Inc.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Inc.
  • Thermo Fischer Scientific Inc.
Note: Product cover images may vary from those shown
Adroll
adroll